NEW YORK, July 16, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating MorphoSys AG (Nasdaq: MOR), relating to a tender offer from Novartis BidCo AG. Under the terms of the offer, MorphoSys shareholders will receive €68.00 per share they own. Click here for ...

NEW YORK, July 15, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating MorphoSys AG (Nasdaq: MOR), relating to a tender offer from Novartis BidCo AG. Under the terms of the offer, MorphoSys shareholders will receive €68.00 per share they own. Click here for more ...

About Mullen Mullen Automotive (NASDAQ: MULN) is a Southern California-based automotive company building the next generation of commercial electric vehicles ("EVs") with two United States-based vehicle plants located in Tunica, Mississippi, (120,000 square feet) and Mishawaka, Indiana (650,000 square feet). In August 2023, Mullen began commercial vehicle production in Tunica. In September 2023, Mullen received IRS approval for federal EV tax credits on its commercial vehicles with a Qualified Manufacturer d ...

wildpixel A key update to the thesis: downgrading to a hold rating until the deal closes As we predicted in our previous analysis, after phase 3 data of pelabresib, MorphoSys (NASDAQ:MOR) was acquired by Novartis on Feb 2024. MorphoSys's acquisition by Novartis for EUR 2.7 billion, or EUR68 per share. We believe this transaction not only showcases a significant premium over MorphoSys's pre-announcement share price but also underlines the strategic fit between the two companies, particularly in leveragi ...

First Quarter Interim Statement January - March 2024 morphosys Group Interim Statement Contents MorphoSys Group: First Quarter Interim Statement January - March 2024 | 3 | Summary | | --- | --- | | 6 | Group Interim Statement | | 6 | Operating Business Performance | | 14 | Human Resources | | 15 | Financial Analysis | | 24 | Subsequent Events | | 24 | Financial Guidance | | 27 | Group Interim Statement | | 27 | Consolidated Statement of Profit or Loss (IFRS) - (unaudited) | | 28 | Consolidated Balance Sheet ...

Annual Report 2023 Our Clinical Pipeline | Clinical Programs Developed | | --- | | by Partners (Selection) | | | Most advanced development stage | | --- | --- | | Program | launchel | | Indication | | | Pelabresib | | | MANIFEST-2 / Myelofibrosis | | | MANIFEST / Myelofibrosis/essential thrombocythemia | | | Tulmimetostat | | | Advanced solid tumors/ | | | hematologic malignancies | | Non-Financial Re https://reports.n Most advanced Key Figures (IFRS) In February 2024, Incyte obtained exclusive rights world ...

Business Combination and Takeover Offer - MorphoSys entered into a business combination agreement with Novartis, with Novartis offering €68.00 per share, valuing the total equity at €2.7 billion[29][30]. - The offer price represents a premium of 94% and 142% on the volume-weighted average price over the last month and three months, respectively, as of January 25, 2024[30]. - The Management Board and Supervisory Board of MorphoSys intend to recommend acceptance of the Novartis Takeover Offer, which is subject to a minimum acceptance threshold of 65%[31]. - Novartis intends to submit a voluntary public takeover offer for all ordinary shares at an offer price of €68.00 per share in cash, with a minimum acceptance threshold of 65% of share capital[50]. - The closing of the Novartis Takeover Offer is expected in the first half of 2024, pending regulatory clearances[31]. - The closing of the Novartis takeover offer is expected in the first half of 2024, contingent upon regulatory clearances and other customary closing conditions[50]. - If regulatory conditions are not satisfied by February 5, 2025, the Novartis takeover offer will terminate[52]. - Following the completion of the Novartis takeover offer, the liquidity and market value of the remaining ordinary shares could decline significantly, potentially leading to their removal from stock indices[54]. - The free float in ordinary shares and ADSs will be significantly lower post-takeover, adversely affecting liquidity and potentially increasing price volatility[57]. - If the takeover is not completed, the price of ordinary shares may decline due to market premium assumptions[58]. - Novartis may control 75% or more of ordinary shares post-takeover, enabling it to initiate a domination and/or profit and loss transfer agreement, which could disadvantage minority shareholders[61]. - Shareholders who do not tender their shares may receive lower value in a post-completion reorganization compared to the offer price[62]. Financial Performance and Funding - MorphoSys has incurred significant losses since inception and anticipates continued losses in the future[43]. - The consolidated net loss for the year ended December 31, 2023, was €189.7 million, with an accumulated deficit of approximately €1,013.1 million[77]. - The company may need to raise additional funding, which may not be available on acceptable terms, potentially delaying product development efforts[43]. - The company may not be able to secure additional capital needed for the development and commercialization of its product candidates[43]. - The company has sufficient liquid funds to ensure operations until early 2026, but external financing opportunities are currently limited[76]. - The company anticipates incurring significant transaction fees and costs related to the Novartis Takeover Offer, which may adversely affect its financial condition[69]. - Future funding requirements will depend on various factors, including regulatory approval timelines and commercialization success[74]. - If the company is unable to obtain timely funding or if revenues from collaborations fall short, it may need to significantly curtail or discontinue development programs, impacting financial condition and operations[84]. Product Development and Market Acceptance - The commercial success of MorphoSys' products will depend on market acceptance by physicians, patients, and third-party payers[43]. - The company’s ability to generate revenue and achieve profitability is contingent on successful product development and regulatory approvals[79]. - The company is preparing regulatory filings for pelabresib in the U.S. and EU based on the MANIFEST-2 study, with the potential for significant market opportunities[97]. - Clinical trials for product candidates like pelabresib and tulmimetostat are resource-intensive and may face delays, impacting the ability to obtain regulatory approvals and commercialize products[98]. - The company must maintain sales and marketing capabilities or enter into agreements with third parties to successfully commercialize its product candidates[89]. - The inability to recruit and retain effective sales personnel could hinder the commercialization of approved medicines[93]. - The commercial success of the company's products will depend on market acceptance by physicians, patients, and payers, which is influenced by factors such as efficacy, safety, and pricing[87]. Regulatory and Compliance Risks - Regulatory approval processes are lengthy and unpredictable, potentially delaying the commercialization of product candidates[110]. - The company may face significant costs and delays in obtaining regulatory approvals across different jurisdictions due to varying requirements[114]. - Disruptions at the U.S. FDA and other agencies could hinder the approval process for new products, negatively impacting the company's business[115]. - Regulatory authorities may impose penalties, require additional clinical trials, or withdraw product approvals if compliance issues arise[126]. - The company is subject to stringent global privacy and data protection requirements, including the GDPR, which imposes significant penalties for non-compliance[219]. - Non-compliance with the GDPR can result in fines of up to €20 million or 4% of total worldwide annual turnover, whichever is higher[220]. Intellectual Property and Competition - The company faces risks related to intellectual property protection, which could hinder its ability to compete effectively in the market[163]. - The company may face challenges in maintaining patent protection due to compliance with various procedural requirements imposed by governmental patent agencies[171]. - The company’s commercial success depends significantly on the ability to operate without infringing third-party patents, which could limit the development of product candidates[185]. - The company faces significant competition from major pharmaceutical and biotechnology companies, which may impact the development and commercialization of its products[137]. - The in-licensing and acquisition of third-party intellectual property rights is competitive, and established companies may have advantages over the company[199]. Operational and Supply Chain Challenges - The company does not own manufacturing facilities and depends on contract manufacturing organizations (CMOs) for clinical and commercial supplies, increasing vulnerability to supply chain disruptions[158]. - Any contamination or manufacturing issues could lead to significant delays, inventory shortages, or product recalls, impacting overall business operations[162]. - The complexity of manufacturing processes requires significant expertise and investment, and any production difficulties could halt supply for clinical trials or commercial sales[161]. - The company relies on third-party suppliers for drug production, which may lead to insufficient quantities and quality issues, adversely affecting commercialization efforts[152]. Personnel and Management - The company may struggle to attract and retain key personnel, which is critical for achieving research and commercialization objectives[207]. - The company may face challenges in retaining key personnel during and after the Novartis Takeover Offer, which could impact operations[72].

Business Update This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including the expectations regarding Monjuvi's ability to treat patients with relapsed or refractory diffuse large B-cell lymphoma ("DLBCL"), the further clinical development of tafasitamab, including ongoing confirmatory trials, additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals for tafasitamab as ...

MorphoSys AG (NASDAQ:MOR) Q3 2023 Earnings Conference Call November 16, 2023 8:00 AM ET Conference Call Participants I would now like to turn the conference over to Julia Neugebauer. Please go ahead. Julia Neugebauer - Head of IR Jean-Paul Kress - CEO Tim Demuth - Chief Research and Development Officer Lucinda Crabtree - CFO Operator A - Julia Neugebauer Before we begin, I'd like to remind you on Slide 2, that some of the statements made during the call today are forward-looking statements, including statem ...

Half-Year Report JANUARY – JUNE 2023 morphosys Contents MorphoSys Group: Half-Year Report January – June 2023 3 Summary MorphoSys - II/2023 2 5 Interim Group Management Report 5 Operating Business Performance Strategy and Group Management 13 Corporate Developments 13 General Business and Market Environment 13 14 Intellectual Property Human Resources 15 Financial Analysis 16 Interim Consolidated Financial Statements 21 21 Consolidated Statement of Profit or Loss (IFRS) Consolidated Statement of Comprehensive ...